Cervical Cancer in the Greater Accra and Ashanti Regions of Ghana

abstract

Purpose Cervical cancer is a common cancer among women worldwide. An estimated 528,000 new cases and 266,000 deaths occurred in 2012. More than 85% of invasive cervical cancer cases occur in low- and middle-income countries. Cervical cancer ranks as the most common cancer among women in Ghana. We conducted a retrospective study to assess the descriptive epidemiology of cervical cancer in Ghana. We describe cervical cancer incidence and mortality rates for the regions served by two large hospitals in Ghana.

Patients and Methods Information for women diagnosed with invasive cervical cancer between 2010 and 2013 was collected from the Komfo Anokye and Korle Bu Teaching Hospitals through review of medical, computer, and pathology records at the oncology units and the obstetrics and gynecology departments. Telephone interviews were also conducted with patients and relatives. Data were analyzed using summary statistics.

Results A total of 1,725 women with cervical cancer were included in the study. Their ages ranged from 11 to 100 years (mean, 56.9 years). The histology of the primary tumor was the basis of diagnosis in 77.5% of women and a clinical diagnosis was made in 22.5% of women. For the 1,336 women for whom tumor grade was available, 34.3% were moderately differentiated tumors. Late stage at presentation was common. The incidence and mortality rates of cervical cancer increased with age up until the 75 to 79—year age group and began to decrease at older ages. The Greater Accra region had higher overall incidence and mortality rates than the Ashanti region.

Conclusion Our study suggests that improvements in the application of preventive strategies could considerably reduce the burden of cervical cancer in Ghana and other low- and middle-income countries. The study provides important information to inform policy on cancer prevention and control in Ghana.

J Glob Oncol 3. © 2016 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License

Yvonne Nartey Philip C. Hill Kwabena Amo-Antwi Kofi M. Nyarko Joel Yarney Brian Cox

Author affiliations and support information (if applicable) appear at the end of this article.

Corresponding author:
Brian Cox, BSc(Hons),
MBChB, PhD, Hugh Adam
Cancer Epidemiology Unit,
Department of Preventive
and Social Medicine,
University of Otago, PO
Box 56, Dunedin, New
Zealand; e-mail: brian.
cox@otago.ac.nz.

INTRODUCTION

Cancer causes more deaths in the world than HIV/ AIDS, tuberculosis, or malaria. Among female cancers, cervical cancer is the fourth most common in the world, with an estimated 528,000 new cases in 2012.² Despite the fact that cervical cancer is potentially preventable through vaccination and screening, more than 250,000 women per annum are estimated to die of the disease worldwide.² Incidence and mortality have declined in most high-income countries, mainly as a result of the introduction of cervical screening. However, this is not the case in most low- and middle-income countries, where approximately 85% of the disease occurs.² The incidence and mortality rates are high in Africa and some parts of Asia, and are low in Australasia and West Asia.²

In Ghana, cervical cancer is the most common cancer among women, with an estimated 3,052 new cases and 1,556 deaths in 2012.² Despite the

magnitude of the problem, accurate data on cervical cancer incidence and mortality are not available. Currently, there are two hospital-based cancer registries, located in the two large tertiary referral hospitals: Komfo Anokye Teaching Hospital (KATH), Kumasi, and Korle Bu Teaching Hospital (KBTH), Accra. These hospitals are the main referral centers where patients with malignancy are diagnosed and treated, and they see most cases of cervical cancer in Ghana, receiving referrals from all over the country.

The registry at KATH has recently been converted into a population-based cancer registry to cover the city of Kumasi. Ghana is divided into 10 administrative regions. The KATH total catchment area covers approximately 50% of the population of Ghana. The KBTH catchment area covers the entire southern part of Ghana, but the hospital also receives patients from other parts of the country. Hence its catchment area is not as well defined.

Several studies of cancer in Ghana have focused on all cancers and have mainly been institution-based studies without a reference population. 5-7 Additionally, no previous research has tried to assess both the cervical cancer incidence and mortality in Ghana and link the data from the two referral hospitals. Knowing the incidence and mortality rates of cervical cancer is important for the formulation of policy and implementation of control measures. This study examined the characteristics of cases of cervical cancer in Ghana and estimated the incidence and mortality rates in two regions of the country.

PATIENTS AND METHODS

The study population consisted of all histologically confirmed and suspected cases of invasive cervical cancer in the oncology units and the obstetrics and gynecology departments at the KATH and the KBTH between 2010 and 2013. We reviewed paper-based (medical), electronic, and pathology records at the oncology units and the obstetrics and gynecology departments of the two hospitals. We collected information about women newly diagnosed with invasive cervical cancer during the 2010 to 2013 time period.

One hundred twenty-eight deaths from cervical cancer were recorded in patients' medical records. Most of the women were lost to follow-up at the two hospitals. Hence information on the outcome of disease (whether women were alive or dead) could not be obtained from review of paper-based and electronic records for the majority of women. However, we attempted to contact all women with a diagnosis of cervical cancer by telephone to obtain basic descriptive and outcome information for this study. For those who could not be reached as a result of death or other reasons, their relatives were contacted. For some women with cervical cancer, the hospital did not have any contact information.

For each department, available information for women with cervical cancer was abstracted from paper-based, electronic, and pathology records onto a standard data collection sheet. Once data from all departments were reviewed for accuracy, the following variables were used to link cases between departments: histology report number, patient's name, age, and telephone number. After linking the data from the two departments and removing duplicates, data were stripped of all identifiers and the final data set was defined for analysis. Because deaths from cervical cancer were only obtained for cases from 2010, only the mortality rates for the 2012 to 2013 periods

are presented because most women in Ghana who die as a result of cervical cancer do so within 2 years.

Approval to conduct the study was sought from the University of Otago Ethics (Health) Committee, Ghana Health Service Ethical Committee and the Committee on Human Research, Publication and Ethics of the Kwame Nkrumah University of Science and Technology and KATH, Ghana. The two hospitals also have internal ethical committees that assess proposed research to take place in the hospitals; the research was also submitted to these committees.

Statistical Analysis

We used STATA version 12.1 (STATA Corporation, College Station, TX) for the data analysis. Frequencies were run for all variables for the purposes of describing proportions or percentages. Statistical tests were performed using the χ^2 and Fisher's exact tests. Statistical significance was determined at a P value < .05.

Population data from the Greater Accra and Ashanti regions were obtained from the 2010 Population and Housing Census in Ghana. The census provided information on the population by region of residence, age, and sex. The census data were not extrapolated for 2011 to 2013 because little increase in population was expected for that time period. The population data from the Ghana Statistical Service showed that there was a <1% increase in the population from 2010 to 2013.

The place of residence was obtained from the medical records and was verified during telephone interview for those who could be contacted. The place of residence had not changed for the majority of women (approximately 95%) and was similar to that recorded in the medical records. To calculate the person-years, the number of females in a region (as estimated by the 2010 census) was multiplied by four (the number of years the cases were accrued) for each age group for incidence and by two for mortality.

Cervical cancer mortality rates were also calculated. Death ascertainment was done by telephone interview of relatives and review of medical records. The deaths recorded in the medical records agreed with those obtained by telephone interview when relatives of women were contacted. To provide regional comparisons adjusted for age, the age-standardized rate (ASR; with 95% CI) was calculated using the direct method and applied to the WHO world standard

Table 1. Demographic Characteristics of 1,725 Women With Cervical Cancer

Characteristic	No. (N = 1,725)	%				
Age group, years						
≤ 29	29	1.7				
30-39	157	9.1				
40-49	364	21.1				
50-59	448	26.0				
≥ 60	721	41.8				
Missing	6	0.3				
Ethnic group*						
Ewe	158	9.2				
Akan	837	48.5				
Ga/Adangbe	156	9.0				
Mole Dagbane	21	1.2				
Guan	11	0.6				
Frafra	14	0.8				
Others	104	6.0				
Non-Ghana ethnicity	103	6.0				
Missing	321	18.7				
Region of residence						
Greater Accra	499	28.9				
Eastern	188	10.9				
Volta	71	4.1				
Central	144	8.4				
Ashanti	441	25.6				
Western	106	6.1				
Upper East	17	1.0				
Upper West	9	0.5				
Brong Ahafo	104	6.0				
Northern	19	1.1				
Non-Ghana residents	100	5.8				
Missing	27	1.6				
Region of birth						
Greater Accra	168	9.7				
Eastern	235	13.6				
Volta	143	8.3				
Central	132	7.7				
Ashanti	347	20.1				
Western	87	5.0				
Upper East	32	1.9				
Upper West	17	1.0				
Brong Ahafo	95	5.5				
Northern	34	2.0				
Non-Ghana	115	6.7				
Missing	320	18.5				
(Continued in next column)						

Table 1. Demographic Characteristics of 1,725 Women With Cervical Cancer (Continued)

Characteristic	No. (N = 1,725)	%
Marital status		
Single	213	12.4
Married	754	43.7
Divorced	159	9.2
Separated	11	0.6
Widowed	323	18.7
Missing	265	15.4
Education		
None	358	20.8
Primary	123	7.1
Junior high	188	10.9
Senior high	61	3.5
Tertiary	51	3.0
Missing	944	54.7
Religion		
Christian	1,341	77.7
Muslim	164	9.5
Traditional	10	0.6
Other	12	0.7
Missing	198	11.5
Occupation		
Unemployed	317	18.4
Trader	567	32.9
Farmer	446	25.8
Teacher	22	1.3
Hairdresser	13	0.7
Seamstress	18	1.0
Businesswoman	15	0.9
Caterer	12	0.7
Other	89	5.2
Missing	226	13.1

^{*}A combination of data from both medical record and telephone interview.

population for each region. For crude and agespecific rates, 95% CIs were calculated using the binomial exact method.

RESULTS

The basic demographic characteristics of women diagnosed with cervical cancer (recorded) are shown in Table 1. A total of 1,725 women with cervical cancer were identified for the 2010 to 2013 time period in the two hospitals. The majority of women with cervical cancer were recruited through the records of the oncology units. The

mean age at diagnosis was 56.9 years (range, 11 to 100 years). One subject, whose age was recorded as 11 years, was diagnosed with adenocarcinoma of the cervix. However, the type of adenocarcinoma was not stated. Most of the women (58.7%) with cervical cancer were of a trader or farmer occupation.

Histology of the primary site formed the basis of the diagnosis for the majority of the women (Table 2). Among women with histologically confirmed cervical cancer, squamous cell carcinoma was the most common histologic type (64.9%). Among those for whom tumor grade was available, moderate differentiation was most common (34.3%). The size of the cervical tumor was not measured for most of the women (54.1%). The distribution of International Federation of Gynecology and Obstetrics stages were as follows: stage I, n = 90 (5.2%), stage III, n = 428 (24.8%), stage III, n = 631 (36.6%), and stage IV, n = 162 (9.4%). For 24% of

Table 2. Tumor Characteristics

Basis of diagnosis Clinical 389 22.5 Histology of primary 1,336 77.5 Histologic type 77.5 1,119 64.9 ADC 145 8.4 Adenosquamous 7 0.4 Other 11 0.6 Missing 443 25.7 Grade of differentiation Vell differentiated 172 10.0 Moderately differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor Measured 791 45.9 Unmeasured 934 54.1 Stage I 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4 Unstaged 414 24.0	Characteristic	No. (N = 1,725)	%
Histology of primary 1,336 77.5 Histologic type 7 0.4 SCC 1,119 64.9 ADC 145 8.4 Adenosquamous 7 0.4 Other 11 0.6 Missing 443 25.7 Grade of differentiation 25.7 10.0 Well differentiated 172 10.0 Moderately differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor Measured 791 45.9 Unmeasured 934 54.1 Stage 1 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Basis of diagnosis		
Histologic type SCC	Clinical	389	22.5
SCC 1,119 64.9 ADC 145 8.4 Adenosquamous 7 0.4 Other 11 0.6 Missing 443 25.7 Grade of differentiation 32.7 34.3 Well differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor Measured 791 45.9 Unmeasured 934 54.1 Stage 1 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Histology of primary	1,336	77.5
ADC 145 8.4 Adenosquamous 7 0.4 Other 11 0.6 Missing 443 25.7 Grade of differentiation Well differentiated 172 10.0 Moderately differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor Measured 791 45.9 Unmeasured 934 54.1 Stage I 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Histologic type		
Adenosquamous 7 0.4 Other 11 0.6 Missing 443 25.7 Grade of differentiation 325.7 34.3 Well differentiated 172 10.0 Moderately differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor 791 45.9 Unmeasured 934 54.1 Stage 1 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	SCC	1,119	64.9
Other 11 0.6 Missing 443 25.7 Grade of differentiation 32.7 10.0 Well differentiated 172 10.0 Moderately differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor Measured 791 45.9 Unmeasured 934 54.1 Stage 1 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	ADC	145	8.4
Missing 443 25.7 Grade of differentiation 25.7 Well differentiated 172 10.0 Moderately differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor 791 45.9 Unmeasured 934 54.1 Stage 1 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Adenosquamous	7	0.4
Grade of differentiation Well differentiated 172 10.0 Moderately differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor Measured 791 45.9 Unmeasured 934 54.1 Stage I 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Other	11	0.6
Well differentiated 172 10.0 Moderately differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor 791 45.9 Unmeasured 934 54.1 Stage 1 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Missing	443	25.7
Moderately differentiated 592 34.3 Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor 791 45.9 Unmeasured 934 54.1 Stage 1 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Grade of differentiation		
Poorly differentiated 238 13.8 Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor 791 45.9 Unmeasured 934 54.1 Stage I 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Well differentiated	172	10.0
Undifferentiated 334 19.4 Missing 389 22.5 Size of tumor Measured 791 45.9 Unmeasured 934 54.1 Stage I 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Moderately differentiated	592	34.3
Missing 389 22.5 Size of tumor 791 45.9 Unmeasured 934 54.1 Stage 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Poorly differentiated	238	13.8
Size of tumor Measured 791 45.9 Unmeasured 934 54.1 Stage 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Undifferentiated	334	19.4
Measured 791 45.9 Unmeasured 934 54.1 Stage 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Missing	389	22.5
Unmeasured 934 54.1 Stage I 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Size of tumor		
Stage I 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Measured	791	45.9
I 90 5.2 II 428 24.8 III 631 36.6 IV 162 9.4	Unmeasured	934	54.1
428 24.8 11 631 36.6 1V 162 9.4	Stage		
III	1	90	5.2
IV 162 9.4	II	428	24.8
	III	631	36.6
Unstaged 414 24.0	IV	162	9.4
	Unstaged	414	24.0

Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma.

women, no staging was recorded, although 40% of the 414 with no stage were documented as having advanced disease. There was a statistically significant difference between the two hospitals with respect to tumor characteristics (Table 3). Younger women were more likely to receive both external beam radiation and brachytherapy compared with older women (data not shown).

Table 4 shows the age-specific incidence rates for the Greater Accra and Ashanti regions for the period 2010 to 2013. There were 949 and 676 women with newly diagnosed cervical cancer at KBTH and KATH, respectively, during the 2010 to 2013 time period. The largest number of cases was diagnosed for the Greater Accra region. The majority of women with cervical cancer were ≥ 40 years of age.

The crude incidence rates for the Greater Accra and Ashanti regions during the 2010 to 2013 period were 14.5 (95% CI, 13.6 to 15.4) and 9.1 (95% CI, 8.4 to 9.8) per 100,000 personyears, respectively. As expected, the incidence of cervical cancer increased with age for both regions. The incidence rates began to increase noticeably from age 25 to 29 years for Greater Accra and 30 to 34 years for the Ashanti region. Incidence rates were highest for women 70 to 74 years of age in Greater Accra (113.8; 95% CI, 92.3 to 138.9) and women 75 to 79 years of age in the Ashanti region (91.3; 95% CI, 71.6 to 114.8). The ASR (world standard population) for the Greater Accra and Ashanti regions for incidence was 24.5 (95% CI, 22.9 to 26.1) and 14.0 (95% CI, 12.9 to 15.1) per 100,000, respectively.

Table 5 presents the age-specific mortality for Greater Accra and the Ashanti region for the period 2012 to 2013. A total of 215 and 101 deaths from cervical cancer were recorded at KBTH and KATH, respectively, between 2012 and 2013. The majority of deaths from cervical cancer occurred in women ≥ 40 years of age. Mortality rates also increased to 75 to 79 years of age for both regions. The crude mortality rate was higher for Greater Accra (8.7; 95% CI, 7.6 to 10.0) compared with the Ashanti region (3.9; 95% CI, 3.1 to 4.7). The ASR (world standard population) for mortality was also higher in the Greater Accra region (14.7; 95% CI, 12.7 to 16.7) compared with the Ashanti region (5.3; 95% CI, 4.2 to 6.3).

DISCUSSION

In this study, we found that the majority of the women with cervical cancer in Ghana presented with advanced disease. We also estimated the

Table 3. Distribution of Tumor Characteristics Between Komfo Anokye Teaching Hospital and Korle Bu Teaching Hospital

Characteristic	КВТН	KATH	Total
Basis of diagnosis			
Clinical	291	98	389
Histology	754	582	1,336
χ^2		$\chi^2 = 42.6$	P < .001
Histologic type			_
SCC	606	513	1,119
ADC	88	57	145
Adenosquamous	7	0	7
Other	10	1	11
Fisher's exact			P = .002
Grade of differentiation			
Well differentiated	125	47	172
Moderately differentiated	284	308	592
Poorly differentiated	110	128	238
Undifferentiated	235	99	334
χ^2		$\chi^2 = 72.1$	P < .001
FIGO stage			
1	50	40	90
II	267	161	428
III	315	316	631
IV	100	62	162
χ^2		$\chi^2 = 18.7$	P < .001

NOTE. Excludes missing values.

Abbreviations: ADC, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; KATH, Komfo Anokye Teaching Hospital; KBTH, Korle Bu Teaching Hospital; SCC, squamous cell carcinoma.

incidence and mortality rates of cervical cancer in two large regions of the country. These data provide important information that can be compared with the findings from other studies and global estimates with respect to the epidemiology of cervical cancer.

That the majority of the women with cervical cancer presented with advanced disease is consistent with findings from other parts of Africa. ¹⁰⁻¹³ This may be related to personal factors as well as poor access to health care. Patients may delay visiting the hospital because they are not aware of the signs and symptoms of the disease, and the cost of diagnosis and treatment may be an impediment. Studies have reported a low level of knowledge of cervical cancer among Ghanaian women and men. ^{14,15} Additionally, traditional and alternative medical practitioners constitute a significant proportion of the health care delivery system in Ghana. Because of their accessibility, affordability, and cultural role, traditional medicines are

an important aspect of the health system. These practitioners are the first point of contact for many health-related issues and this is often associated with a late stage of cancer at diagnosis. 12,16 The occupations of trader or farmer were the most common among women with cervical cancer. These occupations have been associated with cervical cancer in some studies. 17,18

The incidence rates of cervical cancer across the two regions in this study were lower than the Globocan estimate of 35.4 per 100,000 populations,² which used rates in neighboring populations to estimate the rates in Ghana. Not all possible data sources in the Greater Accra and Ashanti regions were able to be included in the data collection. There are three hospitals that offer radiotherapy for cancer: KATH, KBTH, and the Swedish Ghana Medical Centre. The latter is a private oncology center that provides radiotherapy (excluding brachytherapy) and chemotherapy but not surgery. Patients attending this hospital are those who can afford private medical care. Thus, the majority of women are more likely to be referred to KATH and KBTH.

There are also three hospitals that offer radical surgery for gynecologic cancer: KATH, KBTH, and Battor Catholic Hospital. Data were not obtained from the Battor Catholic Hospital. However, some women were referred to KBTH from this hospital. Women who require radiotherapy are mostly referred to KATH and KBTH because these are the only hospitals in the country with the requisite human resources and logistics to manage cancer cases. ¹⁹

The study may also have missed cases among residents who may have sought treatment outside the two regions or had not been diagnosed before death. The exact number of cases is difficult to estimate because there currently exists no national database of cases of diseases seen in other health facilities. ¹⁹ With the few radiotherapy centers in West Africa, it is unlikely that women would have obtained treatment in other countries.

Some women were clinically diagnosed with cervical cancer without histologic confirmation. For women with cervical cancer identified through the review of electronic records at the obstetrics and gynecology department at KBTH, the electronic records had no information on histology reports. The pathology records at the pathology department were reviewed to identify the histology reports of these women. Only a few pathology reports (5.4%) were obtained directly from the pathology department at KBTH. The pathology reports for the rest of the women diagnosed with cervical cancer,

Table 4. Age-Specific Incidence Rate (per 100,000 person-years) for Greater Accra and Ashanti Regions for the Period 2010 to 2013

Greater Accra Region

	dicater Acera Region			Asilaliti Negioli		
Age Group (years)	No. of Patient Cases	Age-Specific Rate	95% CI	No. of Patient Cases	Age-Specific Rate	95% CI
10-14	0	0.0	0.0 to 0.5	1	0.1	0.0 to 0.5
15-19	0	0.0	0.0 to 0.4	0	0.0	0.0 to 0.4
20-24	6	0.6	0.2 to 1.4	2	0.2	0.0 to 0.7
25-29	13	1.4	0.7 to 2.4	4	0.4	0.1 to 1.1
30-34	25	3.4	2.2 to 5.1	14	2.0	1.1 to 3.3
35-39	55	9.6	7.3 to 12.5	41	6.9	4.9 to 9.3
40-44	77	17.4	13.7 to 21.8	71	15.0	11.7 to 19.0
45-49	118	34.9	28.9 to 41.8	77	20.6	16.2 to 25.7
50-54	135	47.2	39.6 to 55.8	91	27.1	21.9 to 33.3
55-59	125	66.4	55.3 to 79.1	70	34.2	26.6 to 43.2
60-64	118	81.1	67.1 to 97.1	60	35.3	27.0 to 45.5
65-69	72	75.9	59.4 to 95.6	47	41.9	30.8 to 55.7
70-74	97	113.8	92.3 to 138.9	75	50.7	39.8 to 63.5
75-79	52	98.3	73.4 to 128.9	73	91.3	71.6 to 114.8
80-84	30	73.4	49.5 to 104.7	29	44.3	29.7 to 63.6
≥ 85	23	52.3	33.2 to 78.5	18	24.8	14.7 to 39.1
Unknown age	3			3		
Crude rate	949	14.5	13.6 to 15.4	676	9.1	8.4 to 9.8
ASR		24.5	22.9 to 26.1		14.0	12.9 to 15.1

NOTE. Excludes 96 and four women who did not live in Ghana's Greater Accra and Ashanti regions, respectively. Abbreviation: ASR, age-standardized rate.

as recorded from the electronic records at KBTH, were not located. It is probable that biopsies were not performed for those women or that the samples were taken to a laboratory outside of these hospitals. Additionally, it could be the case that patients refused to return to the hospital for a biopsy to be done. This information could not be verified because patients of the obstetrics and gynecology department at KBTH take their medical folders home (ie, the folder that contains the patient's medical records). From the review of paper-based medical records, < 1% of women with an initial clinical diagnosis of cervical cancer had a later histology report that did not agree with the clinical diagnosis. Additionally, because women were referred from other hospitals, there was little chance that the two physicians would both misdiagnose the disease.

It is unlikely that women with cervical cancer have been misclassified in this study. After cases were recorded, they were cross-checked carefully by a gynecologic oncologist and the study team to ensure that cases met suitable diagnostic criteria. However, the high number of women for whom some of the data were missing limits the precision of some of the results obtained.

The Greater Accra region had the highest cervical cancer incidence and mortality rates. One possible explanation for the higher incidence rates in the Greater Accra region may include the geographical coverage of KBTH, urbanization, and a historically high prevalence of sexually transmitted infections in the region. The estimate for the Ashanti region was higher than what has been reported in previous studies. ^{19,20}

Ashanti Region

The incidence of cervical cancer increased with age in this study. Of interest, the incidence increased with ages from 50 to 54 years when a reduction at older ages is more common.² However, the higher than expected incidence in older ages may represent high exposure to human papillomavirus (HPV) in these generations when they were younger or an older age at diagnosis. In this study, cervical cancer incidence peaked in women 75 to 79 years of age in the Ashanti region and 70 to 74 years old in the Greater Accra region. It is possible that exposure to HPV may have been, on average, at a younger age in the Greater Accra region.

The presence of high-risk oncogenic HPV DNA is the major cause of cervical cancer. In most

Table 5. Age-Specific Mortality Rate (per 100,000 person-years) for Greater Accra and Ashanti Regions for the Period 2012 to 2013

Greater Accra Region

Ashanti Region

Age Group (years)	No. of Deaths	Age-Specific Rate	95% CI	No. of Deaths	Age-Specific Rate	95% CI
20-24	0	0.0	0.0 to 0.8	0	0.0	0.0 to 0.7
25-29	2	0.4	0.1 to 1.6	1	0.2	0.0 to 1.3
30-34	1	0.3	0.0 to 1.5	2	0.6	0.1 to 2.0
35-39	9	3.1	1.4 to 6.0	3	1.0	0.2 to 2.9
40-44	13	5.9	3.1 to 10.1	6	2.5	0.9 to 5.5
45-49	21	12.4	7.7 to 19.0	10	5.3	2.6 to 9.8
50-54	35	24.5	17.0 to 34.0	15	8.9	5.0 to 14.8
55-59	30	31.9	21.5 to 45.5	11	10.7	5.4 to 19.2
60-64	36	49.5	34.7 to 68.5	8	9.4	4.1 to 18.6
65-69	17	35.9	20.9 to 57.4	8	14.3	6.2 to 28.1
70-74	20	46.9	28.7 to 72.5	15	20.3	11.3 to 33.4
75-79	17	64.3	37.5 to 102.9	11	27.5	13.7 to 49.2
80-84	9	44.0	20.1 to 83.5	4	12.2	3.3 to 31.3
≥ 85	4	18.2	5.0 to 46.6	6	16.5	6.1 to 35.9
Unknown age	1			1		
Crude rate	215	8.7	7.6 to 10.0	101	3.9	3.1 to 4.7
ASR		14.7	12.7 to 16.7		5.3	4.2 to 6.3

NOTE. Excludes four women who did not live in Ghana or the Greater Accra region. Abbreviation: ASR, age-standardized rate.

populations, the prevalence of HPV DNA is higher among sexually active young women. ²¹⁻²³ However, a second peak in HPV DNA prevalence at older ages has been reported in some countries, particularly those in Southern America and Africa. ²⁴⁻²⁶ Currently, the age-specific prevalence of HPV DNA among the Ghanaian female population is unknown. However, a second peak in HPV DNA prevalence might be expected in middle-aged women on the basis of the high cervical cancer incidence rate reported for older women.

The cervical cancer mortality also increased with age in this study. This is a common observation. ² Younger women were more likely to have cervical cancer of an earlier stage compared with older women, possibly because they were more likely to recognize symptoms

early or were diagnosed through screening at antenatal clinics. In addition to the stage at presentation, younger women were more likely to receive therapy with a curative intent, which may contribute to the lower mortality rates in younger women.

In conclusion, this study has provided a summary of the epidemiology of cervical cancer in Ghana. Late stage at diagnosis was common, and it is clear that cervical cancer is an important public health issue. Considerable improvement in patient outcomes in low- to middle-income countries may be achieved through initially raising awareness and knowledge of the disease to encourage risk reduction and early diagnosis.

DOI: https://doi.org/10.1200/JGO.2016.005744 Published online on jgo.org on October 5, 2016.

AUTHOR CONTRIBUTIONS

Conception and design: Yvonne Nartey, Philip C. Hill, Kwabena Amo-Antwi, Kofi M. Nyarko, Brian Cox

Financial support: Brian Cox

Administrative support: Kofi M. Nyarko, Joel Yarney, Brian Cox Provision of study materials or patients: Brian Cox

Collection and assembly of data: All authors

Data analysis and interpretation: Yvonne Nartey, Philip C. Hill, Brian Cox

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.

For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Yvonne Nartey

No relationship to disclose

Philip C. Hill

No relationship to disclose

Kwabena Amo-Antwi

No relationship to disclose

Kofi M. Nyarko

No relationship to disclose

Joel Yarnev

No relationship to disclose

Brian Cox

No relationship to disclose

ACKOWLEDGMENT

We thank the staff of the Komfo Anokye Teaching Hospital (KATH) and the Korle Bu Teaching Hospital (KBTH) cancer registries for assisting with case ascertainment. We are extremely grateful to all of those who contributed in various ways to the study and acknowledge Nelson Damale, MD, Samuel Anenyi Obed, MD, R.A. Kwame Aryee, MD, Mumuni Kareem, MD, Baawiah Osei Bonsu, MD, Nana Afriyie, Asobonteng Attah Nkrumah, Joycelyn Sarfo-Frimpong, Baffour Awuah Ofosu, Nancy Appiah, Freda Kwarteng Boampong, Agartha Agyei Boadi, Mallet Sankah Kodi, Philip Oduro, Isaac Agyemang Duah, Charles Akoto Aidoo, Ernest Agbenyeke, and Raymond Atiemo Danso for their great work during the data collection at the KATH and the KBTH.

Affiliations

Yvonne Nartey, Philip C. Hill, and Brian Cox, University of Otago, Dunedin, New Zealand; Kwabena Amo-Antwi, Komfo Anokye Teaching Hospital, Kumasi; Kofi M. Nyarko, Ghana Health Service; and Joel Yarney, Korle Bu Teaching Hospital, Accra, Ghana.

Support

Supported by the Directors' Cancer Research Trust (B.C.). The Department of Preventive and Social Medicine and the Directors' Cancer Research Trust provided funding for the study.

REFERENCES

- 1. American Cancer Society: Overview of the global cancer and tobacco burden, and our global programs. http://www.cancer.org/aboutus/globalhealth/ourglobalprograms/index
- 2. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France, International Agency for Research on Cancer, 2013. http://globocan.iarc.fr
- 3. Komfo Anokye Teaching Hospital: Annual Report 2012. Kumasi, Ghana, Komfo Anokye Teaching Hospital, 2012.
- 4. Calys-Tagoe BN, Yarney J, Kenu E, et al: Profile of cancer patients' seen at Korle Bu Teaching Hospital in Ghana (a cancer registry review). BMC Res Notes 7:577, 2014
- Wiredu EK, Armah HB: Cancer mortality patterns in Ghana: A 10-year review of autopsies and hospital mortality. BMC Public Health 6:159, 2006
- 6. Gyasi R, Tettey Y: Childhood deaths from malignant neoplasms in Accra. Ghana Med J 41:78-81, 2007
- 7. Der EM, Gyasi RK, Tettey Y, et al: Triple-negative breast cancer in Ghanaian women: The Korle Bu Teaching Hospital experience. Breast J 21:627-633. 2015
- 8. Ghana Statistical Service: 2010 Population and Housing Census. Summary Report of Final Results. Accra, Ghana, Sakoa Press Limited, 2012
- 9. Ahmad O, Boschi-Pinto C, Lopez AD, et al: Age Standardization of Rates: A New WHO Standard. Geneva, Switzerland, World Health Organization, 2001
- 10. Maranga IO, Hampson L, Oliver AW, et al: Analysis of factors contributing to the low survival of cervical cancer patients undergoing radiotherapy in Kenya. PLoS One 8:e78411, 2013
- 11. Clegg-Lamptey J, Hodasi W: A study of breast cancer in Korle Bu Teaching Hospital: Assessing the impact of health education. Ghana Med J 41:72-77, 2007
- 12. Clegg-Lamptey J, Dakubo J, Attobra YN: Why do breast cancer patients report late or abscond during treatment in Ghana? A pilot study. Ghana Med J 43:127-131, 2009
- 13. Anorlu RI, Orakwue CO, Oyeneyin L, et al: Late presentation of patients with cervical cancer to a tertiary hospital in Lagos: What is responsible? Eur J Gynaecol Oncol 25:729-732, 2004
- 14. Ebu NI, Mupepi SC, Siakwa MP, et al: Knowledge, practice, and barriers toward cervical cancer screening in Elmina, Southern Ghana. Int J Womens Health 7:31-39, 2014
- 15. Williams MS, Amoateng P: Knowledge and beliefs about cervical cancer screening among men in Kumasi, Ghana. Ghana Med J 46:147-151, 2012

- Clegg-Lamptey JN, Dakubo JC, Attobra YN: Psychosocial aspects of breast cancer treatment in Accra, Ghana. East Afr Med J 86:348-353, 2009
- 17. Adewuyi SA, Shittu SO, Rafindadi AH: Sociodemographic and clinicopathologic characterization of cervical cancers in northern Nigeria. Eur J Gynaecol Oncol 29:61-64, 2008
- 18. Alterman T, Burnett C, Peipins L, et al: Occupation and cervical cancer: An opportunity for prevention. J Womens Health 6:649-657, 1997
- 19. Laryea DO, Awuah B, Amoako YA, et al: Cancer incidence in Ghana, 2012: Evidence from a population-based cancer registry. BMC Cancer 14:362, 2014
- 20. O'Brien KS, Soliman AS, Awuah B, et al: Establishing effective registration systems in resource-limited settings: Cancer registration in Kumasi, Ghana. J Registry Manag 40:70-77, 2013
- 21. Dunne EF, Unger ER, Sternberg M, et al: Prevalence of HPV infection among females in the United States. JAMA 297: 813-819, 2007
- 22. Bauer HM, Hildesheim A, Schiffman MH, et al: Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 20:274-278, 1993
- 23. Burk RD, Kelly P, Feldman J, et al: Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 23:333-341, 1996
- 24. Lazcano-Ponce E, Herrero R, Muñoz N, et al: Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 91:412-420, 2001
- 25. Herrero R, Castle PE, Schiffman M, et al: Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191:1796-1807, 2005
- 26. Thomas JO, Herrero R, Omigbodun AA, et al: Prevalence of papillomavirus infection in women in Ibadan, Nigeria: A population-based study. Br J Cancer 90:638-645, 2004